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O B J E C T I V E S This study sought to assess the prognostic utility of echocardiographic dyssynchrony
for health status improvement after cardiac resynchronization therapy (CRT).
B A C KG ROUND Echocardiographic measures of dyssynchrony have been proposed for patient
selection for CRT, but prospective validation studies are lacking.
METHOD S A prospective cohort of 324 patients from 53 centers with moderate to severe heart failure,
left ventricular dysfunction, QRS 130 ms, and available echocardiographic and health status information
were identiﬁed from the PROSPECT (Predictors of Response to Cardiac Re-Synchronization Therapy) trial,
which evaluated the prognostic utility of dyssynchrony measures in CRT recipients. The association of 12
echocardiographic dyssynchrony parameters with 6-month improvement in health status, as measured by
the Kansas City Cardiomyopathy Questionnaire (KCCQ), was assessed both as a continuous variable and by
responder status (∆KCCQ 10 points reﬂecting moderate to large improvement).
R E S U L T S Of 12 pre-deﬁned dyssynchrony parameters, only 3 were consistently reported: interven-
tricular mechanical delay (IVMD), left ventricular ﬁlling time relative to the cardiac cycle (LVFT), and left
ventricular pre-ejection interval. After multivariable adjustment, IVMD (5.18, 95% conﬁdence interval
[CI]: 0.76 to 9.60; p  0.02) and LVFT (5.19, 95% CI: 0.45 to 0.94; p  0.03) were independently
associated with 6-month improvements in KCCQ. Patients with 6-month improvements in KCCQ had
lower subsequent mortality (adjusted hazard ratio [HR] for each 5-point improvement: 0.83; 95% CI: 0.72
to 0.93; p  0.03). Additionally, IVMD was associated with CRT responder status (for ∆KCCQ 10
points: odds ratio [OR]: 1.85; 95% CI: 1.12 to 3.05; p 0.03), whereas LVFT was not (OR: 1.63; 95% CI: 0.85
to 3.11; p  0.14). Patients classiﬁed as health status responders had a 76% lower subsequent risk of
all-cause mortality (adjusted HR: 0.24; 95% CI: 0.07 to 0.84; p  0.03).
CONC L U S I O N S The presence of pre-implantation IVMD and LVFT was associated with 6-month
health status improvement, and IVMD was associated with a signiﬁcant CRT response. These echocardio-
graphic factors may help clinicians counsel patients regarding their likelihood of symptomatic improvement
with CRT. (PROSPECT: Predictors of Response to Cardiac Re-Synchronization Therapy; NCT00253357) (J Am
Coll Cardiol Img 2010;3:451–60) © 2010 by the American College of Cardiology Foundation
From the *Mid America Heart Institute and the University of Missouri, Kansas City, Missouri; †The Christ Hospital, Ohio
Heart and Vascular Center, and the Lindner Clinical Trial Center, Cincinnati, Ohio; ‡Fondazione IRCCS Policlinico S.
Matteo, Pavia, Italy; §Medtronic Bakken Research Center, Maastricht, the Netherlands; University of Michigan Division of
Cardiovascular Medicine, Ann Arbor, Michigan; and the VA Ann Arbor Health Services Research and Development Center
of Excellence, Ann Arbor, Michigan. Medtronic Inc. provided funding and manufactured the cardiac resynchronization therapy
system used in this study. Dr. Chung has received a research grant for PROSPECT investigators from Medtronic ($10,000)
and is a consultant/advisory board member for Medtronic ($10,000). Dr. Ghio has received a research grant for PROSPECT
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452he primary goals of heart failure treatment
are to prolong survival and to improve pa-
tients’ health status. Cardiac resynchroniza-
tion therapy (CRT) has previously been
hown to reduce symptoms (1), hospitalizations (2),
nd mortality (3) in patients with moderate to
evere heart failure, left ventricular systolic dysfunc-
ion, and electrocardiographic evidence of ventric-
lar dyssynchrony. Although most patients benefit
rom CRT, there is a gradient of response, with
0% to 40% of CRT recipients receiving little
ymptomatic improvement (1,4). One possible ex-
lanation is that a prolonged QRS duration may
ot be the optimal marker of mechanical dyssyn-
hrony. Because the presumed physiologic mecha-
nism underlying CRT is to reduce dys-
synchrony, more direct assessments of
ventricular dyssynchrony could improve
patient selection and optimize CRT use.
Although a variety of echocardiographic
parameters of dyssynchrony have been
identified (5–8), multicenter prospective
studies evaluating the feasibility of their
measurement or their prognostic utility in
predicting improvements in health status
(symptoms, function, and quality of life)
have not been performed.
The Kansas City Cardiomyopathy
Questionnaire (KCCQ) is a validated
disease-specific measure of patient health
status in heart failure (9,10). The KCCQ
is easy to administer; offers patient-
centered insights into health status not
available with traditional risk factors, bi-
omarkers, or noninvasive tests; and can be
serially monitored (11). Baseline assess-
ment with the KCCQ has been shown to
predict future hospitalization and mortal-
ity (9,11), and its prognostic utility over
ore traditional markers of heart failure severity,
ncluding the New York Heart Association
NYHA) functional class and the 6-min walk test,
as been previously reported (10). Given that a
rincipal goal of CRT is to improve patients’ health
tatus, determining which pre-implantation clinical
haracteristics and dyssynchrony parameters are as-
ociated with improvements in health status would
nvestigators ($10,000), is a consultant/advisory board member for the
eceived a grant for ECHO core laboratory ($10,000). Dr. Gerrit
pproximately $10,000 worth of Medtronic stock shares. Dr. Spertus has r
nd has developed and owns the copyrights for the Kansas City Cardiom
ore
tion
ion
ire
ire
ycleanuscript received September 4, 2008; revised manuscript received Augustnhance patient selection and empower patients
ith additional prognostic information for in-
ormed decision making.
Accordingly, the PROSPECT (Predictors of
esponse to Cardiac Re-Synchronization Therapy)
rial (12) was used to prospectively evaluate which
linical variables and pre-defined echocardiographic
arkers of dyssynchrony predict health status im-
rovement with CRT. Our goal was to determine
he feasibility of measuring these echocardiographic
arkers and to develop a parsimonious risk model
o evaluate whether these measures were associated
ith health status improvement after CRT.
E T H O D S
tudy population. The PROSPECT trial is a pro-
pective, international, multicenter, nonrandomized
tudy designed to evaluate whether echocardio-
raphic measures of dyssynchrony predict clinical
esponse to CRT. The study design has been
reviously described (12,13). Briefly, 467 patients
ith left ventricular ejection fraction 35%,
YHA functional class III or IV heart failure,
nd optimal medical treatment were enrolled
rom 53 centers in the U.S., Asia, and Europe
rom March 2004 to December 2005. Details of
tudy exclusion criteria and CRT programming
or A-V optimization and V-V timing have been
reviously described (13).
For the purposes of the current study, we were
nterested in only those patients with an approved
ndication for CRT by electrocardiographic criteria
nd excluded 41 patients with QRS 130 ms (only
of whom had a QRS duration 120 ms) (Fig. 1).
e also excluded those patients in whom a change
n health status could not be assessed (45 without
aseline KCCQ and 26 without 6-month KCCQ).
inally, we excluded 31 patients in whom all dys-
ynchrony measures on echocardiography were
eemed uninterpretable by the core laboratories (see
he second paragraph of the Clinical variables sec-
ion). Importantly, there were no significant differ-
nces in demographics, clinical characteristics,
aseline health status, or rates of echocardiographic
yssynchrony among patients in the study cohort
nd those who were excluded for the above reasons
tronic steering committee ($10,000), and has
an employee at Medtronic, Inc., and owns
ed a research grant from Medtronic ($10,000),
athy Questionnaire.i Med
r se is
a eceiv
a yopB B R E V I A T I O N S
N D A C R O N YM S
CS Clinical Composite Sc
I confidence interval
RT cardiac resynchroniza
herapy
R hazard ratio
DI integrated discriminat
mprovement
VMD interventricular
echanical delay
CCQ Kansas City
ardiomyopathy Questionna
CCQ-os Kansas City
ardiomyopathy Questionna
verall score
VFT left ventricular filling
ime relative to the cardiac c
VPEI left ventricular pre-
jection interval
YHA New York Heart
ssociation3, 2009, accepted August 10, 2009.
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453Online Appendix A). The final study population
omprised 324 patients.
linical variables. Baseline data on demographics
age, sex, country of origin), clinical variables (left
entricular ejection fraction as determined by the
ore laboratories, QRS duration, body mass index),
edical comorbidities (diabetes mellitus; hyperten-
ion; atrial fibrillation; and prior myocardial infarc-
ion, coronary artery bypass surgery, percutaneous
oronary intervention, or implantable cardioverter-
efibrillator placement), clinical symptoms (chest
ain, dyspnea, orthopnea, pre-syncope, and paroxys-
al nocturnal dyspnea), and medication use
angiotensin-converting enzyme inhibitors or angio-
ensin II receptor blockers, beta-blockers, class I or III
ntiarrhythmic agents, diuretics, aldosterone blockers,
nd lipid-lowering therapy) were collected within 30
ays before CRT implantation in the PROSPECT
rial. Health status assessment was performed at base-
ine and at the 6-month follow-up.
Initially, the PROSPECT trial had planned to
valuate 12 published and unpublished echocardio-
raphic markers of atrioventricular, interventricular,
nd intraventricular dyssynchrony. Details for the
easurement of each parameter performed by the 3
ore laboratories have been previously outlined (13)
nd are described in greater detail in Online Ap-
endix B. In the event that image quality was
etermined to be poor by a core laboratory for a
iven echocardiographic parameter, the value for
hat parameter was considered missing. We ex-
Table 1. Frequency of Missing Data for Dyssynchrony Study Me
Echocardiographic
Method Echocardiographic Dyssy
M-mode Septal-posterior wall motion delay (
Pulsed Doppler Interventricular mechanical delay (40
LV ﬁlling time relative to RR (40%)
LV pre-ejection interval (140 ms)
M-mode  pulsed Doppler Left lateral wall contraction overlap w
Tissue Doppler imaging Time difference between lateral and s
velocity (60 ms)
SD of time to peak velocity (32 ms)
Maximum difference of time to peak v
Maximum difference of time to onset
Delayed longitudinal contraction (2)
Maximum difference of time to peak v
Maximum difference of time to peak d
Echocardiographic assessments for each of the 12 prospectively evaluated dyss
be of poor quality. *Twenty patients in atrial ﬁbrillation or enrolled at sites not
IVCT  isovolumic contraction time; LV  left ventricular.luded 31 patients in whom all 12 dyssynchrony
easures were deemed uninterpretable by the core
aboratories. Due to the technical challenges in-
olved in obtaining high-quality images for many of
hese measures, we also determined a priori to
xclude from our analysis those dyssynchrony pa-
ameters with 20% missing data because their
nclusion would limit the generalizability of study
nferences (Table 1). Therefore, our study focused
n evaluating the prognostic utility of 3 dyssyn-
467 total patients enrolled
426 patients with QRS ≥130 ms
381 patients with 
baseline KCCQ
355 patients available for 
6-month follow-up
324 constituted the final study
population cohort
41 with QRS <130 ms
45 without baseline KC
26 patients without 6-mo
31 patients with echos d
unreadable by core 
Figure 1. Deﬁnition of Study Cohort
KCCQ  Kansas City Cardiomyopathy Questionnaire.
res
rony Measures
Missing Rates Excluding 31
Patients Without Any
Echocardiographic Data
(n  324)
Missing
Patie
Echoc
ms) 80 (24.7%)
) 9 (2.8%)
34 (10.5%)
2 (0.6%)
V ﬁlling (0) 122 (37.7%)
(n  310)*
l peak systolic wall 126 (40.6%)
176 (56.8%)
ity (median) 75 (24.2%)
olic velocity (median) 75 (24.2%)
77 (24.8%)
ity outside IVCT (110 ms) 77 (24.8%)
acement (median) 222 (71.6%)
rony measures were categorized as missing data if the images were determined b
orming tissue Doppler imaging.CQ
nth KCCQ
eemed
labsasu
nch
Rates Including 31
nts Without Any
ardiographic Data
(n  355)
130 111 (31.3%)
ms 40 (11.3%)
65 (18.3%)
33 (9.3%)
ith L 153 (43.1%)
(n  341)*
epta 157 (46.0%)
207 (60.7%)
eloc 106 (34.2%)
syst 106 (34.2%)
108 (31.7%)
eloc 77 (31.7%)
ispl 253 (74.2%)
ynch y the core laboratories to
perf
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454hrony measures (interventricular mechanical delay
IVMD] 40 ms, percentage of cardiac cycle
ength occupied by left ventricular filling time
LVFT] 40%, and left ventricular pre-ejection
nterval [LVPEI] 140 ms) that were obtained
ith reasonable consistency in our study cohort of
24 patients.
utcome assessment. The primary study outcome
as change in patient health status between the
aseline and 6-month visit using the KCCQ,
hich evaluates discrete health status domains for
eart failure (physical limitations, symptoms, so-
ial function, self-efficacy, and quality of life).
he choice of the 6-month follow-up was dic-
ated by the PROSPECT trial design and from
rior clinical trials (2,13). An overall score (KCCQ-
s), based on contributions from each domain
except self-efficacy and recent change in symp-
oms), quantifies the multiple domains of the
CCQ into 1 summary health status measure. We
hose to examine the KCCQ overall summary score
ecause it has been previously shown to be a robust
redictor of future morbidity, mortality, and health
are utilization in heart failure patients (11,14).
cores from the KCCQ-os are transformed to a
cale from 0 to 100, with higher scores denoting
etter health status. Therefore, the primary out-
ome was determined as the difference between the
-month and baseline KCCQ-os scores (KCCQ-
s), with a positive value indicating improvement.
he outcome of KCCQ-os was assessed as a
ontinuous variable for the primary outcome. To
id in clinical interpretability, we also assessed the
KCCQ-os as a categorical variable (secondary
utcome), where KCCQ-os 10 indicated
RT responders with significant health status im-
rovement. The choice of a 10-point improvement in
CCQ-os for CRT responder status was based on
ur prior work, which showed that a 5-point
CCQ-os threshold would be the minimal clinically
ignificant difference and a change 10 points would
epresent a moderately large difference in patients’
ealth status (11).
To establish the clinical importance of our pri-
ary outcome, as a secondary analysis, we examined
he importance of a change in health status at 6
onths with survival. Vital status was determined
t office visits through May 2006, when the last
ROSPECT patient had completed the 6-month
ollow-up visit.
tatistical analysis. Baseline characteristics of the
ntire study cohort were summarized as means with
tandard deviations for continuous variables and mrequencies for categorical variables. The distribu-
ions of continuous covariates were examined and
onfirmed for normality. The bivariate association
etween each variable and the 6-month change in
CCQ-os, adjusted for baseline KCCQ-os, was
etermined with linear regression models. Because
small proportion of clinical and included echocar-
iographic covariates had missing values, we per-
ormed multiple imputation of missing values to
llow for incorporation of all patients and to cor-
ectly account for uncertainty due to missing values.
nalyses were replicated on 10 imputed datasets
nd pooled to obtain final model estimates.
Multivariable linear regression models were then
onstructed to assess which clinical and echocardio-
raphic variables were independently associated with a
ignificant health status change (KCCQ-os). Age,
ex, and baseline KCCQ-os were included in the
odel regardless of significance level, as well as co-
ariates with a significant (p  0.05) association with
he study outcome. Furthermore, to ensure parsimony
nd inclusion of only those variables that provided
ncremental prediction value, we used the approxima-
ion of full-model methodology for model reduction
15). The R2 of the final model was then compared
ith that of a clinical model without dyssynchrony
easures using the log likelihood test to assess
hether the echocardiographic measures significantly
mproved model discrimination. Finally, a scoring
lgorithm was developed by rounding coefficients
rom the multivariable linear regression model.
To aid in the interpretability of our findings, we
ext constructed multivariable logistic regression
odels and assessed which clinical and echocardio-
raphic variables predicted a moderate-to-large
ealth status improvement with CRT (i.e., CRT
esponse with a 10 point increase in KCCQ-os;
eference group 10 points). We then examined
hether these dyssynchrony measures improved
odel discrimination to predict CRT response by
omparing this model with a clinical model without
yssynchrony parameters using C-statistics and the
ntegrated discrimination improvement (IDI) sta-
istic. The IDI is interpreted as the difference
etween improvement in average sensitivity and any
ecrease in average specificity between the com-
ared logistic regression models, which is then
ested against the null hypothesis of IDI  0 (16).
Finally, we examined the importance of our study
nd point—improvements in 6-month health sta-
us—by constructing Kaplan-Meier curves and mul-
ivariable Cox models among surviving patients at 6
onths (i.e., 6-month KCCQ follow-up was time 0
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455n these analyses). These additional analyses evaluated
mprovements in 6-month KCCQ as a continuous
ariable (divided into quartiles) and by responder
tatus. For all analyses, the null hypothesis was eval-
ated at a 2-sided significance level of 0.05 with 95%
onfidence intervals (CIs) calculated. Analyses were
onducted with SAS version 9.1 (SAS Institute, Inc.,
ary, North Carolina), Imputation and Variance Es-
Table 2. Bivariate Associations of Study Covariates With 6-Mon
Baseline Characteristics
Study Population
Frequency (n  32
Baseline KCCQ 11.1%
0 to 25
25 to 50 36.7%
50 to 75 40.7%
75 to 100 11.4%
Echocardiography dyssynchrony
IVMD (40 ms) 52.2%
LVFT (40%) 32.7%
LVPEI (140 ms) 61.7%
Demographics
Age 67.9 11.1
Male sex 71.0%
Clinical data
LVEF 29.4 10.0
QRS duration  SD 164.1 22.9
QRS 160 44.1%
Body mass index 28.3 5.4
Prior myocardial infarction 50.0%
Diabetes mellitus 32.1%
Atrial ﬁbrillation or ﬂutter 20.4%
Prior CABG 29.9%
Prior PCI/PTCA 24.7%
Prior ICD 9.6%
Clinical symptoms
Dyspnea 95.7%
Orthopnea 23.8%
PND 19.1%
Pre-syncope 31.8%
Chest pain 28.7%
Medications
Beta-blockers 86.1%
ACE-I or ARB 91.7%
Lipid-lowering agents 57.4%
Aldosterone blocker 37.0%
Diuretics 82.7%
Class I antiarrhythmic 1.5%
Class III antiarrhythmic 19.8%
Baseline characteristics of the study cohort and their bivariate associations with 6
*Absolute change in continuous KCCQ, adjusted for baseline KCCQ score. †Not
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin II recep
cardiac resynchronization therapy; ICD  implantable cardioverter-deﬁbrillator
Questionnaire; LVEF  left ventricular ejection fraction; LVFT  left ventricular
PCI  percutaneous coronary intervention; PND  paroxysmal nocturnal dyspnea;imation Software (IVEWARE, Ann Arbor, Michi-
an), or R version 2.3.1 (Free Software Foundation,
oston, Massachusetts).
E S U L T S
he mean age of the study cohort was 68 years, of
hich 71% were male. The mean QRS duration
ealth Status Change
Bivariate Association With
6-Month Change in KCCQ*
(95% CI) p Value
Reference†
Reference†
Reference†
Reference†
5.1 (0.8–9.5) 0.02
6.4 (1.6–11.2) 0.009
4.6 (0.1–9.1) 0.04
0.1 (0.1–0.2) 0.55
1.4 (3.1–6.0) 0.54
0.2 (0.4–0.0) 0.08
0.1 (0.0–0.2) 0.10
3.4 (0.8–7.6) 0.11
0.0 (0.4–0.4) 0.84
2.3 (6.5–1.8) 0.27
2.3 (6.8–2.2) 0.31
0.8 (6.0–4.4) 0.76
2.5 (7.0–2.1) 0.29
4.2 (9.0–0.7) 0.09
1.9 (9.0–5.2) 0.60
5.8 (5.0–16.5) 0.29
3.3 (8.4–1.7) 0.19
1.8 (3.5–7.2) 0.49
5.0 (9.6–0.5) 0.03
3.2 (7.8–1.5) 0.18
6.4 (0.1–12.7) 0.05
0.7 (8.3–6.9) 0.86
0.2 (4.0–4.4) 0.93
2.0 (6.3–2.3) 0.34
1.4 (6.9–4.1) 0.61
3.1 (14.3–20.5) 0.73
6.3 (11.5–1.0) 0.02
nth change in KCCQ scores with CRT, adjusted for baseline KCCQ, are presented.
rmined, as the bivariate associations are adjusted for baseline KCCQ score.
locker; CABG  coronary artery bypass graft; CI  conﬁdence interval; CRT 
D  interventricular mechanical delay; KCCQ  Kansas City Cardiomyopathy
g time relative to cardiac cycle; LVPEI  left ventricular pre-ejection interval;th H
4)
-mo
dete
tor b
; IVM
ﬁllinPTCA  percutaneous transluminal coronary angioplasty.
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456as 164  23 ms (43% with QRS 160 ms), and
he mean left ventricular ejection fraction was 29%
Table 2). All patients in the cohort had symptoms
f heart failure, including dyspnea (96%), paroxys-
al nocturnal dyspnea (19%), orthopnea (24%), or
re-syncope (32%). Half the cohort described a
rior history of myocardial infarction, 54% had
rior surgical or percutaneous coronary revascular-
zation therapy, and 29% had chest pain at enroll-
ent. Baseline medical therapy included a high use
f beta-blockers (86%), angiotensin-converting en-
yme inhibitors or angiotensin II receptor blockers
92%), and antiplatelet therapy (79%). Regarding
chocardiographic dyssynchrony, of the 3 pulsed
oppler measures that could be reliably assessed in
t least 80% of patients, evidence of dyssynchrony
y IVMD was observed in 52%, LVFT in 33%, and
VPEI in 62%.
The mean baseline KCCQ-os was 50.7  19.5,
nd the mean 6-month KCCQ-os was 70.9 22.2,
uggesting a marked average improvement in heart
ailure health status with CRT overall (mean
CCQ-os increase of 20.1  21.3). When strati-
ed by baseline KCCQ range categories, patients in
he lower 2 categories (i.e., with the worst baseline
ealth status) had the largest improvements in
-month KCCQ-os compared with the upper 2
ategories: range 1 (KCCQ-os  0 to 24): 26;
ange 2 (KCCQ-os  25 to 49): 29; range 3
KCCQ-os 50 to 74):15; range 4 (KCCQ-os
5 to 100): 5; p  0.001 (Fig. 2).
Adjusted for baseline KCCQ score, a number of
ariables had bivariate associations with 6-month
mprovements in KCCQ-os after CRT (Table 2).
Baseline KCCQ
<25 25 to <50 50 to <75                      ≥75
nadjusted 6-Month Improvements in Health Status Associated
by Baseline KCCQ Range Quartiles
6-month change in KCCQ  1 SD is shown for each baseline
e quartile. An inverse relationship between improvement in
orted symptoms and quality of life (∆KCCQ) associated with CRT
e range quartile of heart failure health status was observed (p 
 chronic resynchronization therapy; KCCQ  Kansas City Car-w
hy Questionnaire.hese included wider QRS duration (p  0.05),
eta-blocker use (p  0.05), and the 3 echocardio-
raphic parameters: IVMD (p 0.02), LVFT (p
.009), and LVPEI (p  0.04).
ultivariable model results. After multivariable ad-
ustment, echocardiographic dyssynchrony as mea-
ured by IVMD (5.18 points on the KCCQ-os,
5% CI: 0.76 to 9.60; p  0.02) and LVFT
5.19 points, 95% CI: 0.45 to 9.94; p 
.03) were independently associated with an im-
rovement in 6-month health status with CRT
Fig. 3A), whereas LVPEI was not. The estimates
or IVMD and LVFT were similar when we as-
igned patients who died before 6 months
ollow-up KCCQ score of 0. Other clinical vari-
bles associated with 6-month improvement in
CCQ-os included male sex, lower baseline
CCQ-os, and beta-blocker use. Table 3 outlines a
coring algorithm based on the estimates from the
egression model to predict absolute changes in
-month KCCQ-os associated with CRT. When
ompared with a model not including dyssynchrony
easures (R2 of 0.21), the inclusion of IVMD and
VFT was found to improve model discrimination
R2 of 0.26; p  0.005). Importantly, an R2 0.20
enotes good model prediction.
Notably, of the 9 echocardiographic parameters
hat had been excluded because of high rates of
issing data, only 1 (maximum difference of time to
nset of systolic velocity) showed a bivariate asso-
iation with 6-month KCCQ change (Online Ap-
endix C). However, this variable was not a signif-
cant predictor of 6-month health status
mprovement when forced into the multivariable
odel (Online Appendix D).
When considered from the perspective of a mod-
rate large improvement in patient health status
10-point increase in KCCQ-os), 65% of patients
ere identified as CRT responders. The rate of
RT response was 64% (23 of 36) for patients with
aseline KCCQ scores of 25, 79% (94 of 119) for
aseline KCCQ scores of 25 to 49, 61% (80 of 132)
or baseline KCCQ scores of 50 to 74, and 38% (14
f 37) for baseline KCCQ scores of 75. After
ultivariable adjustment, IVMD (odds ratio [OR]:
.85, 95% CI: 1.12 to 3.05; p  0.03), lower
aseline KCCQ-os, and beta-blocker use were as-
ociated with CRT response, whereas LVFT (OR:
.63, 95% CI: 0.85 to 3.11; p  0.14) was not. In
ontrast, a history of chest pain and use of class III
ntiarrhythmic medications were associated with
ot having significant health status improvementM
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457o have good discrimination (C-statistic: 0.73) and
alibration (Hosmer-Lemeshow goodness-of-fit
est, p  0.51). When compared with a model
ithout dyssynchrony measures, the model discrim-
nation for CRT response was improved after in-
lusion of IVMD (C-statistic: 0.709 to 0.732 with
 0.05; IDI  0.03 with p  0.001) (Online
ppendix E). Finally, as a sensitivity analysis, we
ound that all model results were not meaningfully
ifferent when analyzed without imputation (On-
ine Appendix F).
urvival by health status improvement. Last, we ex-
mined the importance of achieving 6-month gains
n patients’ health status among recipients of CRT.
atients in the quartile with the smallest gains in
ealth status had the lowest rate of 6-month sur-
ival from the 6-month follow-up assessment:
1.1% for patients in the lowest quartile of KCCQ
mprovement (range: 63 to 6 points), 93.8% in
he second quartile (range: 7 to 18 points), 93.8% in
he third quartile (range: 19 to 34 points), and
5.2% in the highest quartile of KCCQ improve-
ent (35 points) (Fig. 4A). After multivariable
djustment, the 6-month change in KCCQ was a
ignificant predictor of survival (adjusted hazard
atio [HR] for each 5-point improvement in
-month KCCQ: 0.83; 95% CI: 0.72 to 0.93; p 
.03). Similarly, patients classified as health status
esponders had higher crude rates of 6-month
urvival from the 6-month follow-up than nonre-
ponders (98.4% vs. 89.3%; p  0.0003) (Fig. 4B),
nd responder status was associated with a 76%
ower risk of all-cause mortality after multivariable
djustment (HR 0.24; 95% CI: 0.07 to 0.84; p
.03).
I S C U S S I O N
he PROSPECT trial is the first large-scale mul-
icenter clinical study to prospectively evaluate the
easibility and performance of multiple echocardio-
raphic measures of mechanical dyssynchrony in
redicting health status benefits from CRT. There
ere significant challenges in obtaining accurate,
eliable measurements for the majority of dyssyn-
hrony parameters, and only 3 were obtained with
ufficient consistency to warrant further consider-
tion for risk stratification. Despite these chal-
enges, we found that pre-implantation LVFT and
VMD were significantly associated with 6-month
mprovements in heart failure symptoms and qual-
ty of life with CRT, and that IVMD was associ-
ted with marked (10 point increase in KCCQ wcores) improvements in CRT response. In addi-
ion, significant heterogeneity in baseline health
tatus in this population of patients with NYHA
unctional class III or IV heart failure was observed,
6-Month Change in KCCQ Score
More
Improvement
Less
Improvement
Baseline KCCQ
(for each 10-point decrement)
Age (10 years)
Male Sex
Interventricular Mechanical Delay
(≥40 ms)
LV Filling Time (≤40%)
Beta-Blocker Use
4.88 (3.77, 6.00)
0.95 (-0.96, 2.87)
5.39 (0.54, 10.24)
5.18 (0.76, 9.60)
5.19 (0.45, 9.94)
7.98 (1.66, 14.29
-10 -5 0 5 10 15
Odds Ratio (95% CI)
More LikelyLess Likely
Baseline KCCQ
(for each 10-point decrement)
Age (10 years)
Male Sex
Interventricular Mechanical Delay
(≥40 ms)
Chest Pain
Class III Antiarrhythmic Use
Beta-Blocker Use
1.38 (1.20, 1.59
0.97 (0.77, 1.21)
1.85 (1.12, 
2.32 (1.
0.54 (0.31, 0.93)
0.53 (0.29, 0.99)
0.25 0.50 1.00 2.00
0.94 (0.52, 1.68)
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Figure 3. Predictors of 6-Month Changes in Health Status With
Multivariable model predictors of a signiﬁcant 6-month change in K
associated with CRT are presented as a continuous (A) and a binary
responder outcome. The presence of dyssynchrony, as measured by
and LVFT, was found to independently predict 6-month improveme
health status with CRT. The CRT response was deﬁned as a 6-month
increase of 10 points in KCCQ scores. CI  conﬁdence interval; CR
diac resynchronization therapy; IVMD  interventricular mechanical
KCCQ  Kansas City Cardiomyopathy Questionnaire; LVFT  left ve
ﬁlling time relative to the cardiac cycle 40%.)
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458reatest benefit from CRT. Lastly, patients with
arge improvements in health status at 6-month
ollow-up were found to have significantly higher
urvival than patients with minimal health status
esponse after CRT. This suggests that a limited
ulsed Doppler echocardiographic study and base-
ine health status screening may help identify a
ubgroup of patients most likely to derive health
tatus improvement with CRT, which was found to
e associated with higher rates of overall survival.
Prior studies have suggested a wide variety of
yssynchrony measures that may improve patient
election for CRT (5– 8). Many of these studies,
owever, were single-center studies with small
ample sizes, evaluated only 1 or 2 dyssynchrony
easures at a time, used nonclinical end points,
r enrolled patients only when the specific mea-
ure of dyssynchrony could be determined. Con-
idering these limitations, a key rationale for the
ROSPECT trial was to examine the feasibility in
btaining different measures of mechanical dyssyn-
hrony prospectively across multiple centers and to
valuate the external validity of these parameters.
hereas dyssynchrony measured by pulsed Dopp-
er imaging (IVMD, LVFT, LVPEI) was obtain-
ble for most patients in the PROSPECT trial,
yssynchrony measures assessed with M-mode or
issue Doppler imaging inconsistently yielded ade-
uate image quality for reliable interpretation. Dif-
culty in obtaining high-quality images for many of
hese parameters was an unanticipated but impor-
ant finding. The PROSPECT trial’s experience
ay have differed from that of prior studies because
f the technical issues associated with the use of
issue Doppler imaging for timing measurements
Table 3. Scoring Algorithm Using Pre-Implantation Variables
to Predict 6-Month Change in KCCQ With CRT
Variables Points*
Model intercept 8
Baseline KCCQ
0 to 24 20
25 to 49 23
50 to 74 8
75 to 100 0
Male sex 3
Presence of echocardiographic dyssynchrony
IVMD 40 ms 5
LVFT 40% 6
Beta-blocker use 10
*Derived from coefﬁcients of multivariable linear regression model.
Abbreviations as in Table 2.cross multiple sites. This is further compounded by lhe fact that significant levels of intraobserver and
nterobserver variability in obtaining these measures
ave been reported previously (12). Alternatively,
otential publication bias, enrollment bias (e.g.,
xcluding patients in whom measures could not be
btained), or selection bias (e.g., operator or reader
xpertise in tissue Doppler imaging) in prior studies
ay have overestimated the feasibility of obtaining
any measures of dyssynchrony. Regardless, it
uggests that the potential generalizability of many
eported measures of dyssynchrony in routine clin-
cal practice remains far from ideal. Future studies
hould routinely report the number of patients
creened but in whom the dyssynchrony measures
f interest could not be reliably obtained. Mean-
hile, newer imaging modalities for dyssynchrony
e.g., real-time 3-dimensional echocardiography,
peckle tracking) may potentially overcome some of
he problems with the techniques used in the
ROSPECT trial.
Despite the limitations of most dyssynchrony
easures, 3 different measures for dyssynchrony
rom the PROSPECT trial were available for as-
essment: LVFT, IVMD, and LVPEI. We found
hat LVFT and IVMD were significantly associated
ith 6-month improvements in heart failure symp-
oms and quality of life with CRT, and that IVMD
as associated with marked (10 point increase in
CCQ scores) improvements in CRT response.
lthough IVMD also was found to predict a better
utcome in the CARE-HF (Cardiac Resynchroni-
ation in Heart Failure) trial (17,18), the magnitude
f health status benefit has not been previously
uantified. Although interventricular markers of
yssynchrony, such as IVMD, for CRT patient
election may seem intuitive (19), the finding that
horter left ventricular filling times in relation to the
ardiac cycle (LVFT) also identifies patients with
mprovements in health status suggests that dia-
tolic dysfunction may have significant effects on
ymptom burden in the CRT-eligible population
7) or that LVFT may simply be a marker of longer
imes spent in isovolumic contraction (and there-
ore less time available for left ventricular filling)
ue to more severe interventricular dyssynchrony.
Our study extends the findings of a prior report
rom the PROSPECT trial that found that none of
he dyssynchrony measures had sufficient sensitivity
nd specificity for the Clinical Composite Score
CCS) to warrant their use alone to exclude patients
or CRT (12). Importantly, as compared with the
reviously reported outcomes of CCS and reducedeft ventricular end-systolic volume, the discrimina-
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459ion of our model for patient-centered health status
utcomes, including the dyssynchrony measures,
as significantly greater than that reported previ-
usly (C-statistic  0.73 for improvements in
CCQ-assessed health status as compared with a
eak discrimination of 0.60 for CCS and 0.62 for
eft ventricular end-systolic volume reduction of
15%) (12). Nevertheless, it is important to note
hat given the high rate of CRT responder status,
ven a hypothetical model with 95% sensitivity
nd specificity would only yield a modestly ac-
eptable negative predictive value of 90% in the
ROSPECT trial population, thus highlighting the
hallenges in using dyssynchrony measures for pa-
ient selection and coverage decisions regarding
RT implantation. We found, however, that dys-
ynchrony measures do add significant incremental
rognostic information regarding health status im-
rovement with CRT and believe that our scoring
lgorithm (Table 3) can be used by physicians to
ounsel patients regarding their likelihood of health
tatus improvement with CRT. Given that im-
rovements in symptoms and quality of life are of
ubstantial importance to patients when considering
herapy, these data should be useful in describing
he potential risks and benefits of therapy to pa-
ients considering CRT implantation. For example,
70-year-old man with a baseline KCCQ score of
5, IVMD on dyssynchrony evaluation, and on
eta-blockers, would on average be expected to have
33-point improvement in his health status at
-months—a very large improvement in health
tatus. In contrast, a 70-year-old woman with a
aseline KCCQ score of 80 and an otherwise
imilar clinical profile would be expected to have a
ore modest 7-point improvement.
It is also notable that patients with the greatest
ymptom burden and worst quality of life
KCCQ-os 50) were the most likely to benefit
rom CRT, which suggests a gradient of benefit
mong NYHA functional class III and IV heart
ailure patients. Because mean health status scores
mproved in each of the 4 KCCQ-os range ranges
t 6 months, this cannot be explained by simple
egression to the mean. Instead, there is likely a
eiling effect that limits the extent of health status
mprovement for patients in the upper quartiles of
aseline KCCQ-os. However, it is precisely this
imited potential to further improve one’s health
tatus in those with the best health status (and
ighest KCCQ-os scores) that makes the use of
ealth status screening for CRT evaluation attrac-
ive. Indeed, the relative contribution of baseline wCCQ and beta-blocker use relative to echocardio-
raphic dyssynchrony measures in our scoring algo-
ithm (Table 3) underscores the importance of
eighing both clinical factors and imaging results to
dentify those patients most likely to have improve-
ents in symptoms and quality of life with CRT.
Our findings should be interpreted with the
ollowing limitations. Our findings do not account
or the potential survival benefits of CRT and
hould not be used to deny CRT to eligible pa-
ients. Because a number of dyssynchrony measures
ere eliminated from consideration because of poor
mage quality, we were unable to fully assess
hether these measures, if they had been more
eliably obtained, would have had prognostic utility
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460enefit from CRT. Our preliminary analyses for
hese excluded parameters in Online Appendixes C
nd D, however, did not suggest a significant
ssociation with 6-month health status change. Our
nalyses could not account for operator-level varia-
ion in successful CRT lead implantation or patient
ariation in ventricular scar location and size (20),
oth of which are known to affect CRT response.
inally, the PROSPECT trial was a nonrandom-
zed study. Therefore, our findings require external
alidation in future studies.
O N C L U S I O N S
n this large prospective study that evaluated thefailure. J Am Soc Echocardiogr
2006;19:307–13.
D’Agostino RB Jr.,
ating the added prearameters of dyssynchrony in CRT recipients, the
ast majority of measures could not be reliably
btained with sufficient image quality. Among the 3
arameters that could be consistently measured,
re-implantation IVMD and LVFT were indepen-
ent predictors of 6-month health status improve-
ent after CRT. Our scoring algorithm, using
hese measures in conjunction with other baseline
linical and health status characteristics, may help
uide physicians to counsel patients regarding their
ikelihood of symptomatic improvement with CRT.
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